武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TAK 武田制药

未开盘 12-20 15:59:59 EST

13.10

+0.09

+0.65%

盘后13.10

+0.000.00%

18:54 EST

最高13.19	最低13.02	成交量162.13万
今开13.11	昨收13.01	日振幅1.31%
总市值415.16亿	流通市值410.14亿	总股本31.70亿
成交额2,130万	换手率0.05%	流通股本31.32亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"TAK","market":"US","secType":"STK","nameCN":"武田制药","latestPrice":13.095,"timestamp":1734728399991,"preClose":13.01,"halted":0,"volume":1621279,"hourTrading":{"tag":"盘后","latestPrice":13.1,"preClose":13.1,"latestTime":"18:54 EST","volume":20,"amount":262,"timestamp":1734738883909},"delay":0,"floatShares":3132025814,"shares":3170361188,"eps":0.63521,"marketStatus":"未开盘","marketStatusCode":0,"change":0.085,"latestTime":"12-20 15:59:59 EST","open":13.105,"high":13.19,"low":13.02,"amount":21303182.906181,"amplitude":0.013067,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.63521,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":0,"listingDate":1545627600000,"adjPreClose":13.01,"adrRate":0.5,"dividendRate":0.000076,"preHourTrading":{"tag":"盘前","latestPrice":13.02,"preClose":13.01,"latestTime":"08:53 EST","volume":125,"amount":1643.14,"timestamp":1734702798582},"postHourTrading":{"tag":"盘后","latestPrice":13.1,"preClose":13.1,"latestTime":"18:54 EST","volume":20,"amount":262,"timestamp":1734738883909},"volumeRatio":1.2298838187327674,"impliedVol":0.2205,"impliedVolPercentile":0.2103},"requestUrl":"/m/hq/s/TAK","defaultTab":"news","newsList":[{"id":"2492957434","title":"金十数据整理：每日美股市场要闻速递（12月17日 周二）","url":"https://stock-news.laohu8.com/highlight/detail?id=2492957434","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492957434?lang=zh_cn&edition=full","pubTime":"2024-12-17 21:47","pubTimestamp":1734443243,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["HK0000306701.USD","NVD","161027","TAK","CVX","MRK","NVDS","2NVD.UK","LU0345770308.USD","BK4503","SG9999014898.SGD","SNVD.UK","TSLL","3NVD.UK","TSYW.SI","META","LU2468319806.SGD","LU2054465674.USD","NVDS.UK","BK4547","LU2505996681.GBP","NGmain","LU0861579265.USD","NVD2.UK","UNG","NVIW.SI","RTX","161631","NFLX","UGAZ","NVDD","TSLA","NVD3.UK","IE00BMPRXR70.SGD","NVDL","DGAZ","IE00BMPRXN33.USD","NVDU","BK4587","QGmain","NVDY","PLTR","LU2420271590.USD","NVDX","LU0683600562.USD","NVDA","LU2097344431.USD"],"gpt_icon":0},{"id":"2492954105","title":"武田制药(TAK.US)CD38单抗在中国再获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954105","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492954105?lang=zh_cn&edition=full","pubTime":"2024-12-17 21:06","pubTimestamp":1734440793,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月16日，中国国家药监局药品审评中心网站最新公示，武田制药1类新药mezagitamab注射剂获得一项新的临床试验默示许可，拟开发治疗原发性免疫性血小板减少症。Mezagitamab治疗旨在提供快速且持续的血小板应答改善，并恢复血小板计数至功能水平。在中国，武田已经完成该产品治疗持续性/慢性原发性免疫性血小板减少症的2期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2488304161","title":"武田制药(TAK.US)与Keros Therapeutics合作开发血液疾病创新疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2488304161","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488304161?lang=zh_cn&edition=full","pubTime":"2024-12-04 15:30","pubTimestamp":1733297410,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Keros Therapeutics今天宣布与武田制药达成一项独家全球开发和商业化许可协议，以推进elritercept的开发。此外，3期临床试验RENEW将很快启动患者招募，研究elritercept在患有极低风险、低风险或中等风险MDS且依赖输血的成人患者中的疗效。自协议生效之日起，武田将负责elritercept的所有开发、生产和商业化工作。根据协议内容，Keros将收到2亿美元的预付款，并有资格获得超过11亿美元的开发、监管及商业里程碑付款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220172.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","TAK","LENZ","BK4007"],"gpt_icon":0},{"id":"2482485092","title":"武田制药2024财年第三财季实现净利润6.17亿美元，同比增加285.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482485092","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482485092?lang=zh_cn&edition=full","pubTime":"2024-11-09 00:00","pubTimestamp":1731081624,"startTime":"0","endTime":"0","summary":"11月9日，武田制药公布财报，公告显示公司2024财年第三财季净利润为6.17亿美元，同比增加285.84%；其中营业收入为78.80亿美元，同比增加9.20%，每股基本收益为0.19美元。机构评级：截至2024年11月9日，当前有13家机构对武田制药目标价做出预测，其中目标均价为15.92美元，其中最低目标价为13.73美元，最高目标价为19.29美元。公司简介：武田药品工业是日本最大的制药公司，2023财年的收入为4.3万亿日元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109000056a224f576&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109000056a224f576&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TAK"],"gpt_icon":0},{"id":"2481925398","title":"武田制药在进博会重申承诺，推动幽门螺杆菌防控助力健康中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2481925398","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481925398?lang=zh_cn&edition=full","pubTime":"2024-11-07 15:23","pubTimestamp":1730964180,"startTime":"0","endTime":"0","summary":"在第七届中国国际进口博览会上，武田制药举办了\"无幽家庭一小步、健康中国一大步\"专场主题发布会，介绍其在幽门螺杆菌治疗领域的布局和未来发展。活动汇聚了消化领域专家、医疗专业人士等，围绕幽门螺杆菌的认知、筛查和治疗展开交流，以提升公众对该感染的认识和防范意识，共同推动\"健康中国\"战略目标。武田制药在消化领域深耕多年，其创新药物富马酸伏诺拉生片已获批用于根除幽门螺杆菌，为患者提供新的治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-11-07/doc-incvfpzf7693581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2481289999","title":"武田(TAK.US)在中国启动两项3期临床试验  针对“过度睡眠”病症推出创新疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2481289999","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481289999?lang=zh_cn&edition=full","pubTime":"2024-11-07 15:18","pubTimestamp":1730963896,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国药物临床试验登记与信息公示平台官网近日公示，武田(TAK.US)在中国启动了两项TAK-861的国际多中心3期临床研究，分别为一项评价TAK-861治疗发作性睡病伴猝倒的疗效和安全性的研究，以及一项在患有选定中枢性睡眠过度疾病的受试者中开展的评价TAK-861长期安全性和耐受性的研究。公开资料显示，TAK-861是一种口服食欲素受体2(OX2R)激动剂。该产品治疗发作性睡病1型(NT1)适应症此前已经被中国NMPA纳入突破性治疗品种，以及获美国FDA授予治疗NT1中过度白天过度嗜睡的突破性疗法认定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1576","03347","BK1141","TAK","BK4007"],"gpt_icon":0},{"id":"2481190223","title":"家无幽 我守护|武田举办幽门螺杆菌主题发布活动 助力健康中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2481190223","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481190223?lang=zh_cn&edition=full","pubTime":"2024-11-07 14:56","pubTimestamp":1730962560,"startTime":"0","endTime":"0","summary":"儿童是幽门螺杆菌感染的高风险群体，主要由父母尤其是母亲传播。感染了幽门螺杆菌的家庭成员始终是潜在的传染源，具有持续传播的可能性。我国幽门螺杆菌感染整体基数大，以家庭为单位防控幽门螺杆菌感染是阻断感染和传播的重要策略，有助于夯实健康中国的基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4550472_ZH50472_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2478151690","title":"武田掀起新一轮裁员潮！专利悬崖、管线调整之后，整合能否找到出路？","url":"https://stock-news.laohu8.com/highlight/detail?id=2478151690","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478151690?lang=zh_cn&edition=full","pubTime":"2024-10-27 18:56","pubTimestamp":1730026591,"startTime":"0","endTime":"0","summary":"武田制药在经历今年多轮裁员后，正计划进一步缩减员工规模。业内人士分析，武田制药近期的裁员决策主要是受到专利到期所带来的市场冲击及其对财务状况的影响。对武田制药而言，当务之急是寻找并推出下一代的主力产品。尽管武田制药通过专利诉讼试图延缓Vyvanse的专利到期，但这一努力并未能有效缓解利润下降的压力。自公布重组计划以来，武田制药已经启动了一连串的裁员措施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241027190022a1eef4bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241027190022a1eef4bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4116","ADHD","IG","CD","TAK","IBD","BK4007"],"gpt_icon":0},{"id":"2475236606","title":"武田制药将在第七届进博会展示多领域创新成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2475236606","media":"中国经济网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475236606?lang=zh_cn&edition=full","pubTime":"2024-10-14 20:37","pubTimestamp":1728909435,"startTime":"0","endTime":"0","summary":"武田制药近日宣布，将在第七届进博会上展现公司“拓维中国”战略的最新进展、核心治疗领域的产品布局以及数字化创新产品和创新成果。今年是武田制药进入中国市场30周年。30年来，武田制药不断升级在华发展战略，持续加码中国市场，构建了从新药开发、生产、药品保障供应及商业化运营的完整药品价值链布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202410143205618987.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202410143205618987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2461301267","title":"中国创新药的出路","url":"https://stock-news.laohu8.com/highlight/detail?id=2461301267","media":"锦缎","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461301267?lang=zh_cn&edition=full","pubTime":"2024-08-23 08:08","pubTimestamp":1724371682,"startTime":"0","endTime":"0","summary":"中国创新药，门前两条路：一条叫速度为王，一条叫全球市场。所以我们始终认为，布局全球市场才是中国创新药企成功的必由之路。纵观一众创新药企，亚盛医药堪称中国创新药企发展的典型样本。01源头创新的价值亚盛医药已经获得FDA授予的2项快速通道以及2项儿童罕见病资格认证，同时还获得16项美国FDA及1项欧盟孤儿药资格认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082308494895b5d5cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082308494895b5d5cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TAK","BK1161","06978","BK1574","06855"],"gpt_icon":0},{"id":"2461374538","title":"中国正成全球生物医药创新策源地——访武田制药全球高级副总裁、武田中国总裁单国洪","url":"https://stock-news.laohu8.com/highlight/detail?id=2461374538","media":"经济日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461374538?lang=zh_cn&edition=full","pubTime":"2024-08-23 05:56","pubTimestamp":1724363784,"startTime":"0","endTime":"0","summary":"“中国是全球第二大经济体，正成为全球生物医药健康领域的重要创新策源地。武田中国将紧抓中国创新机遇，推动新的发展战略。”武田制药全球高级副总裁、武田中国总裁单国洪近日接受经济日报记者采访时表示。20世纪90年代初，看好中国市场潜力的武田制药开始在中国布局业务。1994年，武田制药生产工厂落户天津。1994年至2014年被公司视为在华发展的第一个阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202408233163178762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2458090551","title":"武田再次大裁员！关闭研发中心，大砍产品管线，何时能走出调整螺旋？","url":"https://stock-news.laohu8.com/highlight/detail?id=2458090551","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458090551?lang=zh_cn&edition=full","pubTime":"2024-08-09 17:05","pubTimestamp":1723194344,"startTime":"0","endTime":"0","summary":"日前，武田制药宣布，计划关闭其位于美国加州的研发中心，并在美裁员1000人。与此同时，武田制药的研发管线也经历了一系列调整。此外，武田制药的核心营业利润也下降13.3%。对于净利润急转直下的原因，武田制药将其归咎于多款产品遭遇专利悬崖。然而，披露2023财年报告的同日，武田制药宣布即将关闭圣迭戈研究中心，可能涉及340名员工。在武田制药发布的重组计划中，除了劳动力和公司结构优化计划外，还包括严格的产品管线削减决策等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408091708149f1d20e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408091708149f1d20e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2457900840","title":"武田制药盘中异动 早盘快速拉升5.03%报13.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457900840","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457900840?lang=zh_cn&edition=full","pubTime":"2024-08-07 22:41","pubTimestamp":1723041695,"startTime":"0","endTime":"0","summary":"北京时间2024年08月07日22时41分，武田制药股票出现异动，股价快速拉升5.03%。截至发稿，该股报13.98美元/股，成交量78.3254万股，换手率0.02%，振幅1.20%。武田制药股票所在的制药行业中，整体跌幅为0.66%。武田制药公司简介：武田药品工业是日本最大的制药公司，2023财年的收入为4.3万亿日元。它的地域分布非常多元化，其中50%来自美国，20%来自日本，20%来自欧洲和加拿大。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807224135941ff11e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807224135941ff11e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2457603020","title":"重组血管性血友病因子在华获批，武田制药助力精准治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2457603020","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457603020?lang=zh_cn&edition=full","pubTime":"2024-08-06 09:34","pubTimestamp":1722908040,"startTime":"0","endTime":"0","summary":"注射用伏尼凝血素α是全球首个且目前唯一一个重组血管性血友病因子产品，其获批填补了中国血管性血友病领域的临床治疗空白，有望为患者带来精准治疗的创新选择。VWD女性患者月经增多和产后出血的风险均显著高于一般女性，生育能力多受影响，严重时甚至危及生命。一项Ⅲ期按需治疗临床试验评估了注射用伏尼凝血素α针对重度血管性血友病成人患者的止血疗效，研究了联合或不联合重组凝血因子FVIII的不同给药策略按需治疗和出血事件控制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-08-06/doc-inchsmte8155493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"1139594025","title":"异动解读 | 武田制药新药伏尼凝血素α在华获批 填补血友病治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=1139594025","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139594025?lang=zh_cn&edition=full","pubTime":"2024-08-05 22:13","pubTimestamp":1722867225,"startTime":"0","endTime":"0","summary":"武田制药旗下创新药物注射用伏尼凝血素α近日正式获得国家药品监督管理局批准在中国上市,用于血管性血友病成人患者的按需治疗和出血事件控制,以及围手术期出血管理。注射用伏尼凝血素α是全球首个且目前唯一一个重组血管性血友病因子产品,其获批填补了中国血管性血友病领域的临床治疗空白,为患者带来了精准治疗的创新选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TAK"],"gpt_icon":0},{"id":"2457953726","title":"武田(TAK.US)血友病新药“伏尼凝血素α”在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2457953726","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457953726?lang=zh_cn&edition=full","pubTime":"2024-08-05 19:41","pubTimestamp":1722858099,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月5日，中国国家药监局官网最新公示，武田制药申报的注射用vonicog alfa上市申请已获得批准。根据武田发布的公开资料，注射用vonicog alfa是一款重组血管性血友病因子，本次在中国获批的适应症为用于血管性血友病成人患者的按需治疗和出血事件控制，以及围手术期出血管理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1160174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2457670740","title":"武田注射用伏尼凝血素α正式获批 填补中国血管性血友病临床治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2457670740","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457670740?lang=zh_cn&edition=full","pubTime":"2024-08-05 18:35","pubTimestamp":1722854100,"startTime":"0","endTime":"0","summary":"注射用伏尼凝血素α是全球首个且目前唯一一个重组血管性血友病因子产品[1]，其获批填补了中国血管性血友病领域的临床治疗空白，有望为患者带来精准治疗的创新选择。近年来，武田致力于将我们在罕见出凝血疾病领域丰富的产品管线加速引进中国；注射用伏尼凝血素α的获批，将进一步满足中国血管性血友病成人患者的临床治疗需求，助其改善生活质量，实现自由人生。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4476434_ZH76434_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["TAK","BK4007"],"gpt_icon":0},{"id":"2457753360","title":"武田制药2024财年第二财季实现净利润6.11亿美元，同比减少6.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457753360","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457753360?lang=zh_cn&edition=full","pubTime":"2024-08-05 00:13","pubTimestamp":1722788018,"startTime":"0","endTime":"0","summary":"8月5日，武田制药公布财报，公告显示公司2024财年第二财季净利润为6.11亿美元，同比减少6.00%；其中营业收入为77.52亿美元，同比增加0.71%，每股基本收益为0.19美元。机构评级：截至2024年8月5日，当前有13家机构对武田制药目标价做出预测，其中目标均价为15.42美元，其中最低目标价为13.25美元，最高目标价为18.99美元。公司简介：武田药品工业是日本最大的制药公司，2023财年的收入为4.3万亿日元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805001348957ca931&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805001348957ca931&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TAK"],"gpt_icon":0},{"id":"2456357474","title":"据悉武田制药计划关闭其位于美国加州的研发中心并在美裁员1000人。","url":"https://stock-news.laohu8.com/highlight/detail?id=2456357474","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456357474?lang=zh_cn&edition=full","pubTime":"2024-08-02 17:22","pubTimestamp":1722590536,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2455975165","title":"Takeda Pharmaceutical(TAK.US)：2024年Q1财报实现营收77.52亿美元，前值为73.3亿美元；","url":"https://stock-news.laohu8.com/highlight/detail?id=2455975165","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455975165?lang=zh_cn&edition=full","pubTime":"2024-07-31 14:34","pubTimestamp":1722407670,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["TAK","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.takeda.com","stockEarnings":[{"period":"1week","weight":-0.0242},{"period":"1month","weight":-0.0147},{"period":"3month","weight":-0.1152},{"period":"6month","weight":0.0393},{"period":"1year","weight":-0.0626},{"period":"ytd","weight":-0.0823}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Takeda Pharmaceutical Company Limited是一家在日本注册成立的上市公司成立于1925年1月12日。该公司及其子公司是一家主要的全球制药集团，从事医药产品、非处方药和准药品消费品以及其他医疗保健产品的研究、开发、制造和营销。武田的主要医药产品包括以下治疗领域的药物：胃肠病学、肿瘤学和神经科学。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.03791},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.021005},{"month":3,"riseRate":0.5,"avgChangeRate":-0.007765},{"month":4,"riseRate":0.5,"avgChangeRate":-0.007082},{"month":5,"riseRate":0.5,"avgChangeRate":0.000857},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.019551},{"month":7,"riseRate":0.5,"avgChangeRate":0.0124},{"month":8,"riseRate":0.666667,"avgChangeRate":0.001502},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.021841},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.059656},{"month":11,"riseRate":0.666667,"avgChangeRate":0.06202},{"month":12,"riseRate":0.666667,"avgChangeRate":0.007169}],"exchange":"NYSE","name":"武田制药","nameEN":"Takeda Pharmaceutical Co Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供武田制药(TAK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"武田制药,TAK,武田制药股票,武田制药股票老虎,武田制药股票老虎国际,武田制药行情,武田制药股票行情,武田制药股价,武田制药股市,武田制药股票价格,武田制药股票交易,武田制药股票购买,武田制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供武田制药(TAK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}